fda shortage semaglutide injection products resolved feb 21 2025 declares over GLP-1 prescriptions for weight loss

Kupila SKE, Joki A, Suojanen LU, Pietilinen KH

BioDrugs Clin

Reduces the appearance of dark circles beneath the eyes

As we look to 2026, the story becomes one of defining firsts: the debut of oral GLP-1s, the first loss of exclusivity for a GLP-1 receptor antagonist, and landmark coverage decisions such as obesity medications entering Medicare formularies for obesity as a standalone indication

The functional medicine 5R framework is a step by step strategy designed to address the root causes of poor gut health methodically

Semaglutide is an FDA-approved GLP-1 receptor agonist that works by mimicking a hormone your body produces naturally to regulate appetite and digestion